Skip to main content
. 2019 Jan 2;14(1):e0209153. doi: 10.1371/journal.pone.0209153

Fig 5. Control of EGFRvIII-expressing tumors by Lm-EGFRvIII.

Fig 5

a) C3H mice were left untreated or vaccinated with Lm-EGFRvIIIx5 twice separated by 14 days. 7 days following the last vaccine, mice were challenged with SCCVII-control or SCCVII-EGFRvIII. Ii) 7 days following tumor challenge, EGFRvIII-specific CD8 T cells in the spleen were quantified by IFN-γ ICS. b) i) C3H mice were left untreated or vaccinated with Lm-EGFRvIII twice separated by 14 days. 7 days following the last vaccine, mice were challenged with SCCVII-control on one flank and SCCVII-EGFRvIII on the opposite flank. ii) Size of tumors in unvaccinated animals (left two columns) or vaccinated animals (right two columns) d10 following tumor challenge. c) C3H mice were vaccinated with Lm-OVA as a vector control or Lm-EGFRvIII twice separated by 14 days. 7 days following the last vaccine, mice were challenged with SCCVII-control or SCCVII-EGFRvIII and followed for ii) survival of vaccinated animals. d) C3H mice were implanted with SCCVII-EGFRvIII and left untreated or vaccinated with a single dose of Lm-EGFRvIII on d3 following tumor challenge. Graphs show average tumor growth of treatment groups. Key: * = p<0.05; ** = p< 0.01; *** = p<0.001; **** = p<0.0001 (a- ANOVA; b- T-test; c,d Log rank).